Insmed, Inc. (INSM)
| Market Cap | 2.58B |
| Revenue (ttm) | 221.21M |
| Net Income (ttm) | -415.96M |
| Shares Out | 119.98M |
| EPS (ttm) | -3.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 540,717 |
| Open | 21.88 |
| Previous Close | 21.87 |
| Day's Range | 21.48 - 22.47 |
| 52-Week Range | 16.41 - 34.44 |
| Beta | 1.83 |
| Analysts | Buy |
| Price Target | 50.09 (+132.5%) |
| Earnings Date | Oct 26, 2022 |
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a tr... [Read more...]
Financial Performance
In 2021, Insmed's revenue was $188.46 million, an increase of 14.63% compared to the previous year's $164.41 million. Losses were -$434.65 million, 47.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for INSM stock is "Buy." The 12-month stock price forecast is 50.09, which is an increase of 132.54% from the latest price.
News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Sept. 7, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...
Insmed To Present at Two September Conferences
BRIDGEWATER, N.J. , Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launch --...
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022
BRIDGEWATER, N.J. , July 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
Insmed Names Drayton Wise Chief Commercial Officer
BRIDGEWATER, N.J. , May 23, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference
—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE® (amikacin liposome inhalation suspension) Init...
Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference
BRIDGEWATER, NJ,, May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Insmed Reports First Quarter 2022 Financial Results and Provides Business Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million-- --Seven Clinical Trials Underway; Enrollment ...
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
BRIDGEWATER, N.J. , April 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...
Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference
--Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use of ARIKAYCE® (amikacin liposome inhalation suspension) to be Presented in Poster Discussion Session-- --Analysi...
Insmed To Present at the Cowen 42nd Annual Health Care Conference
BRIDGEWATER, N.J. , March 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -6.74% and 10.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update
BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference
BRIDGEWATER, N.J., Feb. 10, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
Insmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipelin...
BRIDGEWATER, N.J., Jan. 27, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed To Participate in Three November Conferences
BRIDGEWATER, N.J., Nov. 3, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...
New Strong Sell Stocks for October 29th
IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.
Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List
BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
Insmed (INSM) Reports Q3 Loss, Lags Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -15.66% and -2.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?